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Abstract
Background: In earlier work, we found important selection biases when we tried to obtain consent for
participation in a national stroke registry. Recognizing that not all registries will be exempt from requiring
consent for participation, we examine here in greater depth the reasons for the poor accrual of patients
from a systems perspective with a view to obtaining as representative sample as possible.
Methods: We determined the percent of eligible patients who were approached to participate and,
among those approached, the percent who actually consented to participate. In addition we examined the
reasons why people were not approached or did not consent and the variation across sites in the percent
of patients approached and consented. We also considered site variation in restrictions on the accrual and
data collection process imposed by either the local research ethics board or the hospital.
Results: Seventy percent of stroke patients were approached, with wide variations in approach rates
across sites (from: 41% to 86%), and considerable inter-site variation in hospital policies governing patient
accrual. Chief reasons for not approaching were discharge or death before being approached for consent.
Seventeen percent of those approached refused to participate (range: 5% to 75%). Finally, 11% of those
approached did not participate due to language or communication difficulties.
Conclusion: We found wide variation in approach and agree rates across sites that were accounted for,
in part, by different approaches to accrual and idiosyncratic policies of the hospitals. This wide variation in
approach and agree rates raises important challenges for research ethics boards and data protection
authorities in determining when to waive consent requirements, when to press for increased quality
control, when to permit local adaptation of the consent process, and when to permit alternatives to
individual express consent. We offer several suggestions for those registries that require consent for
participation.
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Background
The need for individual consent for the secondary analysis
of existing data or for the use of data in clinical registries
for a broad, long-range research agenda is highly conten-
tious. Some researchers have called for a waiver of consent
requirements for minimal risk research, arguing that
obtaining individual consent would be impracticable and
allowing individuals to opt-out would introduce bias into
analyses [1-5]. Others, however, warn of the blurring of
the distinction between research and clinical care, contin-
ual expansion of secondary uses of data for non-clinical
purposes, and pressures to weaken human subject protec-
tions [6]. The responsibility of weighing the competing
demands of scientific rigour and the protection of human
subjects' rights falls squarely upon research ethics boards
(REBs). In examining how to minimize analytic bias,
waiver of consent is not the only option. In particular,
REBs may first wish to consider what efforts have been
taken to ensure quality control in the recruitment process.
Earlier, we reported selection biases associated with
attempts to obtain consent for participation in a consent-
based acute stroke registry, the Registry of the Canadian
Stroke Network [5]. However, we also noted significant
variation in approach and consent rates across sites, sug-
gesting possible recruitment process issues that deserve
attention. In this paper, we examine more closely the var-
iation in recruitment across sites, and attempt to under-
stand the reasons for variations in patient approach and
agree rates. We do this to assist others who will be devel-
oping consent-based registries, in obtaining a sample that
is as representative as possible of the larger population.
Methods
The Canadian Stroke Network (CSN) is a collaborative
effort of academic researchers, government, industry, and
the non-profit sector, dedicated to decreasing the physical,
social and economic consequences of stroke on the indi-
vidual and on society. The Registry of the Canadian Stroke
Network (RCSN) is a clinical database of patients with
acute stroke patients seen at selected acute care hospitals
across Canada. In this paper, we focus on "Phase 2" of the
RCSN which took place between June 2002 and Decem-
ber  2002. Patients were recruited into the registry by expe-
rienced research nurses. Data collected included
information about patient demographics and clinical
symptoms, their hospital encounter, and quality of life
and functional status (through a follow-up telephone
interview).
We determined the percent of potentially eligible patients
who were approached to participate in the Registry. We
also examined what percent of those who were
approached to participate actually consented to partici-
pate. Nurse-coordinators maintained a log documenting
whether non-participation was due to patient refusal, ina-
bility to consent due to language or another communica-
tion barrier, or inability to approach the patient due to
early discharge or other factors. In addition, we examined
the variation across sites in the percent of patients who
were approached to participate in the Registry and, of
those, the percent who agreed to participate. Finally, we
summarized the barriers encountered at individual sites
through a survey of site coordinators.
Results
Reasons patients were not accrued into the Registry 
(Figure 1)
Overall, 70% of potential participants were approached
and 72% of these were enrolled in the Registry, with an
overall accrual rate of 50.5%. Logistical challenges in
approaching patients accounted for 60% of non-accrual.
Major reasons included: death before the patient could be
approached (10%); discharge from hospital before being
approached (10%); and inability to make contact with the
patient or surrogate after more than 3 attempts (20%).
Of the patients approached, approximately 17% refused
to participate. This is approximately 2.5 times greater than
that encountered in pilot work (unpublished).
Eight percent of patients were unable to consent due to
communication difficulties with no surrogate available.
Another 3% of those approached were not administered
the consent form because their mother tongue (and that
of their surrogate) was not English or French.
Variation in approach, agree, and overall participation 
rates (Figure 2)
The percent of eligible patients approached varied across
sites from 41% to 86%, with a mean of 70%. The agree
rate averaged 74% of those approached (lowest 25%,
highest 95%). Approach and consent rates were not corre-
lated across sites.
Supports and constraints on data collection (Table 1)
There was considerable variation across sites in supports
for and constraints on approaching patients. Only five
sites (25%) had active support from the emergency
department (e.g. notification of new patients, providing
brochures for patients not admitted to hospital). These
sites achieved a substantially higher approach rate than
did the sites without such support (average 80.5% vs.
67%; p < 0.02).
We found approach rates to be lower:
• When lists of potential stroke patients could not be
obtained from the emergency department or the wards
(60.6% vs. 70.4%);BMC Medical Ethics 2006, 7:6 http://www.biomedcentral.com/1472-6939/7/6
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Patient accrual process – phase 2 Figure 1
Patient accrual process – phase 2.
Discharged before approached 138: (4.9% of potential participants)
Not admitted/unable to consent 130 (4.6% of potential participants)
POTENTIAL PARTICIPANTS
n=2823
PATIENTS APPROACHED
n=1979 (70%)
PARTICIPANTS
n=1426
(72.1% of approached / 50.5% of  potential participants)
Not approached
Patient unable to consent & no surrogate 
available: 166 (8.4% of approached)
Language 53 
(2.7% of approached)
Refused 334 
(16.9% of approached)
Dead: 137 (4.8% of potential participants)
Ineligible or >14 days 47 (1.7% of potential participants)
>3 attempts to contact 286 (10.1% of potential participants)
Other 106 (including 2 missing, 3.8% of potential participants)BMC Medical Ethics 2006, 7:6 http://www.biomedcentral.com/1472-6939/7/6
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• When coordinators could not approach patients
directly. In these cases, the physician responsible for care
had to first approach the patient. (59.9% vs. 71.1%); and
• When coordinators could not make contact with the
patients after they had left the hospital (65.7% vs. 72.0%).
None of these results was statistically significant, although
this may have been due to inadequate statistical power.
Approach rates were no different in sites where the local
principal investigator actively participated in the recruit-
ment and where the nurse recruiter worked closely with
the stroke team.
Discussion
We found wide variation across sites in both the rate at
which potentially eligible patients were approached to
participate in the Registry and in consent rate. Based on
our discussions with study coordinators, we learned that
some of the difference in approach rates was due to varia-
tions in the interpretation of provincial data protection
laws, and by site-specific limitations imposed by hospitals
on the conditions under which patients could be
approached. In some cases, the restrictions applied by
hospital administration went over and above those
applied by the research ethics boards or by provincial
laws. In addition, sites receiving support from their emer-
gency department (e.g. notification of new patients, pro-
viding brochures for patients not admitted to hospital)
had substantially higher approach rates.
We observed an overall refusal rate of 17% with wide var-
iation across sites (5% to 75%). This indicates unevenness
in the approach to recruitment across sites. Ideally, it
would be helpful to ask those who refused why they
refused. This information is not available from the Regis-
try. However, in future research projects, where consent is
required, it would be instructive to learn why people
refuse to participate, so as to be responsive to concerns
raised.
Regulatory and governance context
Canadian federal and provincial data protection laws
allow for exemptions from consent for research purposes
where, among other conditions: (a) the research cannot
be achieved without using personal information, and (b)
it is impracticable to obtain consent [7]. However, none of
the provinces' legislation provides clear guidance as to the
circumstances under which obtaining consent may be
deemed impracticable. In Alberta, Saskatchewan, and
Ontario, legislation specifically identifies this to be the
purview of the research ethics board (REBs) [8].
Article 3.4 of the Tri-Council Policy Statement (TCPS) –
the document that articulates the standards in Canada for
REBs of institutions receiving funding from any of the
three major federal granting councils – states that the
"REB  may[our emphasis] also require that a researcher's
access to secondary use of data involving identifying
information be dependent on: (a) the informed consent
of those who contributed data or of authorized third par-
ties;..." [9]. No specific guidance is provided as to the cri-
teria for determining whether or not consent should be
required for secondary use of existing personal informa-
tion for research. However, two of the fundamental guid-
ing ethical principles articulated in the TCPS are respect
for free and informed consent and respect for privacy and
confidentiality. Therefore, to be consistent with the val-
ues, purpose, and protections advanced in the TCPS, the
onus for demonstrating a reasonable exception to the
requirement for consent should fall on the researcher.
In 2005, the Canadian Institutes of Health Research
(CIHR) issued its Best Practices for Protecting Privacy in
Health Research[8]. Element 3 of the document includes
detailed guidance as to the factors to consider when deter-
mining whether or not a research project should receive
exemption from consent for secondary use of personal
information. One of the provisions is quite broad – if, due
to the size of the population, the proportion likely to have
relocated or died, or lack of continuing relationship with
the data holder:
"...there is a risk of introducing bias into the research
because of the loss of data from segments of the popula-
tion that cannot be contacted to seek their consent,
thereby affecting the validity of results and/or defeating
the purpose of the study."
We recognize the risk that this provision runs the risk of
becoming a "trump card" over privacy concerns. Accord-
ingly, it places a heavy onus on REBs to determine when
Approach and agree rates by site: sorted by agree rate Figure 2
Approach and agree rates by site: sorted by agree rate.
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to allow use of the data without consent and when to
press for increased quality control in recruitment. This is
relatively simple when it has been demonstrated that the
vast majority of the potential research participants would
be willing to allow their information to be used. It is much
more difficult when, as we found, a non-trivial proportion
of people approached refuses to participate.
Section 39 of the 2004 Ontario Personal Health Informa-
tion Protection Act permits the disclosure of personal
health information without consent to "prescribed regis-
tries" for the purpose of statistical analysis [12]. A handful
of registries, including the Registry of the Canadian Stroke
Network, are among the prescribed registries [10].
Experience elsewhere
The limited published literature on recruitment suggests
that challenges in variation in recruitment faced by the
Registry of the CSN are not unique. While researchers
associated with the Mayo Clinic in Minnesota were able to
achieve consent rates in excess of 95% to participate in a
broad cross-section of disease-registries, there was varia-
tion both across sites and by diagnosis [11,12].
Table 1: Supports and barriers to patient accrual and mean approach rates
Mean approach rate (n) t-test p value
Sites answering "Yes" Sites answering "No"
Supports Available for the 
Registry
1. Do you work with the 
"Stroke Team" (attend 
ward rounds, discharge 
planning meetings, receive 
referrals or patient lists 
from the team, etc.)
70.4 (11) 69.4 (9) 0.8651
2. Do your physicians 
(attending/investigator/
residents/fellows) help you 
obtain patient consents?
73.0 (9) 71.6 (9) 0.7503
3. Is there a neurology/
stroke prevention clinic 
where TIA/stroke patients 
are seen following 
emergency department 
visits at your hospital?
68.9 (15) 73.0 (5) 0.5084
4. Do you have support 
from your emergency 
department (notification of 
new patients, providing 
brochures for patients not 
admitted to hospital, etc.)
80.5 (5) 66.9 (14) 0.0183
Barriers to Recruitment 1. Will your institution 
allow you to collect the 
minimal dataset on all 
patients?
70.1 (18) 69.0 (2) 0.901
2. Will your institution 
allow you to obtain lists of 
potential stroke patients 
from ED and the wards?
70.4 (19) 60.6 (1) 0.417
3. Will your institution 
allow you to directly 
approach admitted patients 
to consent to participate in 
the Registry?
71.1 (18) 59.9 (2) 0.1962
4. If a "potential" registry 
participant has been 
discharged (or never 
admitted) will your 
institution allow you to 
contact the patient to 
participate in the registry?
72.0 (13) 65.7 (6) 0.2877
5. Will your institution 
allow you to obtain 
telephone consent?
69.2 (6) 69.7 (12) 0.9446BMC Medical Ethics 2006, 7:6 http://www.biomedcentral.com/1472-6939/7/6
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It appears, though, that consent-seeking alone is not
exclusively responsible for incomplete accrual. Across 91
U.K. clinical databases listed under the Directory of Clin-
ical Databases (DoCDat), completeness of patient recruit-
ment appears to be similar for databases that do and do
not require individual consent for enrolment [13].
In a different context, Gross and colleagues examined
patient accrual for 172 clinical trials in four high-impact
medical journals. They found very poor reporting of the
patient accrual process, with only 31 studies (18%)
screening from a consecutive series of patients [14].
Lessons learned
Many researchers will still need to obtain informed con-
sent for patient participation in their registry projects – for
example, where there will be direct patient contact, where
genetic information will be included or linked, or in par-
ticularly stigmatizing medical conditions. Several lessons
can be learned from our experience with developing a
consent-based registry. These lessons are derived from the
data presented in this paper and from our discussions
with site coordinators and co-investigators:
(1) The consent process needs to be thoroughly pilot
tested under 'real-world conditions' with gradual roll-out
to participating sites. One should anticipate ample lead
time to develop, test, and implement the entire concept –
particularly the consenting process and staff responsibili-
ties.
(2) Close communications need to be established early
and maintained with research ethics boards and health
care institutions. This is probably best accomplished
through a single contact-person working with each REB
and hospital from the outset of the project.
(3) Accountability requirements for those responsible for
obtaining consent should be as consistent as possible.
Nurse coordinators in this study had a dual accountabil-
ity: to the central coordinator and to local site principal
investigators.
(4) Consider staging the implementation process, so as to
build on the successes of the less complicated recruitment
scenarios. For example, from the outset, we tried to recruit
patients with transient ischemic attacks. This was ambi-
tious, as these particular patients usually were not admit-
ted to the hospital, and they constituted a large
proportion of our patients not approached.
(5) Use a multi-pronged strategy for recruitment when
potential registry participants have multiple points of
access or care trajectories (e.g. both inpatient and outpa-
tient treatment). Obtaining consent may be more feasible
when repeated outpatient visits allow increased contact
and trust.
(6) Obtain firm support of those departments that have
first contact with target patients (e.g. Emergency) to iden-
tify potential participants and provide them with informa-
tion and support to implement screening processes.
(7) Consider random sampling strategies to reduce work-
load, rather than including all consecutive patients. This
was a strategy we implemented in Phase 2 in institutions
with particularly high volumes of stroke patients. We
found this increased the approach rate.
(8) Ongoing monitoring and feedback on accrual help to
increase and sustain higher accrual rates and interest.
(9) Consent forms in other languages and access to trans-
lators may be required for projects operating in jurisdic-
tions with multi-ethnic populations. Usually, such
hospitals have a roster of translators for such situations.
(10) Elicit ongoing patient feedback – particularly from
those who hesitate or refuse to participate – to ascertain
what concerns they may have. While some refusers may
not wish to share this information, if this is done in a way
that does not pressure patients, then it can provide valua-
ble feedback.
Long-run changes are needed
Concern has been expressed elsewhere that, for multi-cen-
tered studies, the process of research ethics approval is
very time consuming, with considerable duplication of
effort and local idiosyncratic restrictions that offer little
perceived gain [15-17]. In some countries, a centralized
review process has been implemented for such multi-cen-
tered studies. While intended to streamline the review
process, in some cases this has simply added another level
of bureaucracy [18]. Even greater standardization of the
process would be helpful. Assimilation of the CIHR pri-
vacy guidelines into the review process could help to har-
monize the interpretation of acceptable recruitment
practice.
In our study, the chief source of variation in administra-
tive requirements came not from the REBs but from the
data stewards – acute care hospitals. In particular, we
found major differences in (a) ability to coordinate with
the emergency department in the recruitment process; and
(b) hospital policy as to whether, and at what point,
potential registry participants could be approached to par-
ticipate. In part, this can be resolved through education of
health care institutions as to what is permitted by the law.BMC Medical Ethics 2006, 7:6 http://www.biomedcentral.com/1472-6939/7/6
Page 7 of 8
(page number not for citation purposes)
Looking forward, numerous registry and linked electronic
health record data collection activities are being planned
in North America and Europe. Perhaps it is time to re-
think how we go about recruiting patients into these reg-
istries [19]. For example, would it be more efficient to
shift responsibility for patient accrual from managers of
individual projects to the institution and for a network of
institutions to develop common protocols across institu-
tions for obtaining consent for use of clinical records,
obtaining biological samples, follow-up surveys, and link-
age of clinical data with administrative records?
Conclusion
We have described numerous challenges in developing
and implementing a consent-based registry for stroke
patients. We believe that ours is not a unique experience.
Our attempts have led to important sampling biases that
limit the generalizability of our data. We have also dem-
onstrated important quality control issues in conducting
a multi-centered registry. The teasing out of these issues
represents a major challenge to research ethics boards and
data protection authorities who are charged with the
responsibility of determining when to allow collection of
information without consent, when to press for increased
quality control in recruitment, and when to permit local
adaptation of the recruitment process. We hope that the
experience of the Registry of the Canadian Stroke Network
will contribute to future-oriented solutions.
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